Cleveland BioLabs Appoints Dr. Michael Paterno Director of Clinical Operations

Cleveland BioLabs Appoints Dr. Michael Paterno Director of Clinical Operations
BUFFALO, NY, Jun 28, 2010 (MARKETWIRE via COMTEX) -- Cleveland BioLabs, Inc. today announced that the Company has appointed Michael Paterno, O.D. Director of Clinical Operations. Paterno's primary responsibility will be to facilitate the clinical program leading to a successful Biologic License Application submission for CBLB502 as a Medical Radiation Countermeasure with the U.S. Food and Drug Administration (FDA). Paterno will be working closely with the Company's Chief Medical Officer, and regulatory affairs and research and development teams.

Michael Fonstein, Ph.D., Chief Executive Officer and President of Cleveland BioLabs, stated, "We believe Michael's depth of experience and history of success will be valuable as CBLB502 progresses towards submission for FDA licensure for Acute Radiation Syndrome. We look forward to his contributions to the team."

Dr. Paterno brings twenty years of clinical research and development experience to CBLI. Prior to joining the Company, Paterno was Manager, Pharmaceutical Clinical Science at Bausch & Lomb, Inc., where he led teams in the design, implementation, and conduct of Phase I - IV clinical trials in support of new product development. He has contributed to several Investigational New Drug Applications and New Drug Applications in addition to authoring clinical study results for publication. From 1989 to 2004, Paterno held several other clinical research positions at Bausch & Lomb including Manager, Internal Research Clinic; Senior Research Optometrist, Global Vision Care; and Interim Director, Clinical Management, Personal Products Research and Development, among others.

Dr. Paterno holds a Bachelor of Arts in Biological Sciences from the State University of New York at Binghamton, a Bachelor of Science in General Sciences and a Doctor of Optometry degree from the Pennsylvania College of Optometry.

About Cleveland BioLabs, Inc. Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop treatments for cancer and protection of normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the company's website at http://www.cbiolabs.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2009.


Contact:
Rachel Levine
Director Corporate Development & Communications
Cleveland BioLabs, Inc.
T: (646) 284-9439
E: [email protected]

 

 


SOURCE: Cleveland BioLabs, Inc.

mailto:[email protected]

Suggested Articles

After seeing later stage trials come through in obesity, Novo Nordisk is canning two projects that were aiming to help reduce patients’ weight.

T-knife has raised €66 million ($78 million) to take four prospects from its TCR-T-cell platform into the clinic in solid tumor indications.

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.